

NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

Prostate Cancer

Second Guideline Development Group (GDG) meeting

3rd April 2012

Board Room, NCC-C, Park House, Greyfriars Road, Cardiff

ATTENDEES:

GDG Members	
Mr Sean Duffy (SD)	Nicola James (NJ)
Dr Peter Kirkbride (PK)	Prof Howard Kynaston (HK)
Hugh Butcher (HB)	Brian McGlynn (BM)
Dr Sarah Cant (SC)	Kathleen Nuttall (KN)
Prof David Neal (DN)	Dr Jonathan Richenberg (JR)
NCC-C staff	
Angela Bennett (AB)	Matthew Prettyjohns (MP)
Dr Nathan Bromham (NB)	Victoria Titshall (VT)
Dr John Graham (JG)	Mia Schmidt-Hansen (MSH) (<i>during agenda item 2.4l only</i>)
Elise Hasler (EH)	
NICE staff	
Claire Turner (CT)	
Apologies	
Prof Peter Hoskin (PH)	Dr Jonathan Oxley (JO)
Dr Andrew Champion (AC)	

REPORT OF DISCUSSIONS AT THE MEETING

1 Welcome and apologies

SD welcomed everyone to the 2nd meeting of the Prostate Cancer GDG.

Apologies for absence were received from Prof Peter Hoskin, Dr Jon Oxley, and Dr Andy Champion.

2 Declarations of interest

SD noted that the following GDG members have declared the following interests since the last GDG meeting:

- SC declared that her partner works for Sanofi Pasteur (no shares received in benefit). This interest was categorised as non-specific personal family interest.
- PH declared that he is chief investigator for a trial investigating brachytherapy +/- external beam radiotherapy, which received funding from DoH & CRUK. He continues to follow these patients and publish data from the study. This interest was categorised as non-personal pecuniary specific.
- PH declared that he holds a research grant from Varian which pays the salary for a data manager working on HDR boost. This interest has not been categorised as more information is needed from PH.

Web minutes of 2nd Prostate Cancer GDG meeting on 3rd April 2012

- PH declared that his department is reimbursed for studies on abiraterone by Cougar. This interest was categorised as non-personal pecuniary non-specific.
- PH declared that his department is reimbursed for studies on alfaradin by Astellas. This interest was categorised as non-personal pecuniary non-specific.
- PH declared that his department is reimbursed for studies on MDV 3100 by Medivation. This interest was categorised as non-personal pecuniary non-specific.
- PH declared that his department is reimbursed for studies on denosumab by Amgen. This interest was categorised as non-personal pecuniary specific.
- JO declared that he holds shares in GlaxoSmithKline Plc. This interest was categorised as personal pecuniary specific.
- JO declared that he holds shares in AstraZeneca, Novartis and GlaxoSmithKline all held in a fund. This interest was categorised as personal pecuniary specific.
- PH declared that he received travel expenses from Astellas Pharmaceuticals to attend BAUS annual meeting in Liverpool department is reimbursed for studies on alfaradin by Astellas. This interest was categorised as personal pecuniary non-specific.
- HK declared that he is collaborator/lead local investigator for several multi-centre trails and diagnostic studies (biomarker exploration) which are mainly in prostate cancer. This interest was categorised as non-personal pecuniary specific.
- HK declared that he is on the Trail Management Group (but not chief investigator) for the following two MRC Trials:
 - RADICALS – radiotherapy and androgen deprivation in combination after local surgery
 - PATCH – prostate adenocarcinoma: transcutaneous hormones both funded by CTAAC (CRUK). This interest was categorised as non-personal pecuniary specific.
- HK declared that he received an honorarium from Takeda for a symposium speaker fee at the BAUS Annual Meeting for presentation entitled 'surgery for high risk localised prostate cancer'. This interest was categorised as personal pecuniary specific.
- HK declared that he received travel expenses from Ferring Pharmaceuticals to launch the MRC RADICALS trial in Ireland. This interest was categorised as personal pecuniary specific.
- HB declared that he received payment from Macmillan to act as a co-researcher on 'evaluation of NCSI user involvement model'. This interest was categorised as personal pecuniary non-specific.
- HB declared that he is the co chair of the User Partnership Group (UPG) Yorkshire cancer Network. This interest was categorised as personal non-pecuniary.
- HB declared that he is a member of the Macmillan Cancer Support Spiritual Support Task Force. This interest was categorised as personal non-pecuniary.
- HB declared that he is a service user representative, receiving an honorarium from Oxford Brooks University, on a management advisory group research project in nurse led/primary care follow up for prostate cancer. This interest was categorised as personal pecuniary non-specific.
- HB declared that he is a member of the National User Steering Group for Peer review. This interest was categorised as personal non-pecuniary.
- HB declared that he is a service user member of the NCAT MDT Development Steering Group. This interest was categorised as personal non-pecuniary.

Web minutes of 2nd Prostate Cancer GDG meeting on 3rd April 2012

- HB declared that he is deputy chair of the York & District Cancer Partnership Group at York District Hospital. This interest was categorised as personal non-pecuniary.
- JR declared that he moderated at the European Congress Radiology on prostate cancer, attendance fee waived by ECR. This interest was categorised as personal pecuniary non-specific.

No new interests were declared at the meeting. The GDG were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that the necessary action can be taken.

| 4 Discussion

NB gave a presentation on GRADE.

The GDG discussed and amended the PICO tables for topics 4a-b, 5-6, 9a-b, 11a-b and 12a-e.

MP presented his findings on the economic priorities and the GDG discussed.

The GDG agreed to model topics 1 & 2 combined for economic investigation.

5 Close of meeting

SD thanked the GDG for their input to the meeting, reminded them that the next meeting would be on **Friday 18th May 2012**, starting at 10.45 in the Board Room, NCC-C Offices, Greyfriars Road, Cardiff and closed the meeting.